The total profits of Jazz Pharmaceuticals for 2012 was about 30%. Jazz Pharmaceuticals then got an income tax benefit courtesy of the Irish government that bumped Jazz Pharmaceuticals total income to 49%. The 30% net profit margin is typical of many of the larger pharmaceutical companies that produce patent pharmaceuticals.
Jazz Pharmaceuticals will almost assuredly be unable to sustain the 49% margin because the income tax benefit is a temporary incentive.
Teva, which is one of the largest, if not the largest, generic manufacturer of pharmaceuticals, has a net profit margin of 10 to 15%.